11/10/2001
London, UK – 11 October 2001: ReGen Therapeutics Plc (“ReGen” or the “Company”), a company developing a potential treatment for Alzheimer’s disease, announces it is today posting a circular to shareholders (“Circular”) seeking, inter alia, their authority at an Extraordinary General Meeting to be held on 5 November 2001, to issue up to 20,000,000 new ordinary shares pursuant to a proposed placing at 10p per new ordinary share (“Proposed Placing”).
The Proposed Placing is being arranged by Hoodless Brennan & Partners plc, as agent for the Company. The Proposed Placing is not underwritten or guaranteed, although significant indications of interest in participating in the Proposed Placing have been received to date. A further announcement will be made when the results of the Proposed Placing are known.
Application will be made for any new ordinary shares to be issued pursuant to the Placing to be admitted to the Alternative Investment Market of the London Stock Exchange plc. The new ordinary shares will rank pari passu in all respects with existing ordinary shares of ReGen.
The Circular will be available to the public, free of charge, from the office of ReGen, Suite 406, Langham House, 29-30 Margaret Street, London, W1W 8SA
For further information, please contact:
BUCHANAN COMMUNICATIONS
Lisa Baderoon
E-mail: lisab@buchanan.uk.com
Tel No: 020 7466 5000
M: 07721 413496
Members of the public are not eligible to take part in the Placing.
This press release does not constitute or form part of any offer or invitation to purchase, subscribe for or sell any shares or other securities in ReGen nor shall it or any part of it or the fact of its publication form the basis of, or be relied on in connection with, any contract therefore.